生殖補助医療市場：タイプ別、診断別、エンドユーザー別-2025-2030年の世界予測

生殖補助医療市場は、2023年に251億2,000万米ドルと評価され、2024年には295億2,000万米ドルに達すると予測され、CAGR 17.57％で成長し、2030年には780億4,000万米ドルに達すると予測されています。

生殖補助医療（ART）には、体外受精（IVF）、人工授精、凍結保存など、不妊症に対処するための医療処置が含まれます。ARTの必要性は、ライフスタイルの変化、人口の高齢化、多嚢胞性卵巣症候群のような疾患の増加による不妊率の上昇に起因しています。ARTは、個人やカップルの妊娠を助けるためにクリニックや病院で応用され、主に不妊のさまざまな課題を克服しようとする家族向けに提供されています。最終用途分野は主にヘルスケア施設と不妊治療センターです。ART市場は、医療技術の進歩、不妊治療に対する意識の高まり、さまざまな層でART治療が受け入れられつつあることが背景にあります。さらに、多くの地域で政府の支援と有利な規制が市場拡大に寄与しています。主なビジネスチャンスは、施術の成功率を高めるAIや機械学習アルゴリズムなどの技術革新や、不妊治療需要が高まっている新興市場でのサービス拡大から生じています。しかし、課題としては、地域によっては熟練した専門家が不足していることに加え、高額な費用、倫理的な懸念、アクセスが限られていることなどが挙げられます。さらに、社会的・文化的な偏見が採用率の妨げになることもあります。今後の技術革新は、手技の成功率の向上、コストの削減、遺伝子マッピングや患者体験の向上による治療の個別化に焦点が当てられる可能性があります。研究開発にとって重要な分野は、非侵襲的診断ツール、胚選択方法の改善、ホルモン療法代替などです。事業成長のためには、新興市場へのサービス拡大や、初診時の遠隔医療への投資が有益であろう。ART市場はダイナミックであり、技術の進歩と不妊症の有病率の増加によって大きな成長の可能性を秘めています。しかし、持続的な成功のためには、倫理的、文化的、コスト的な課題を克服することが重要です。

市場力学：急速に進化する生殖補助医療市場の主要市場インサイトを公開

生殖補助医療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ストレス、公害、肥満による不妊症患者の増加
  • 新興国におけるヘルスケア支出の増加
  • 卵巣がん、子宮内膜がん、PCOSの増加
• 市場抑制要因
  • 手術に必要な費用が高く、成功率が低いこと
• 市場機会
  • 政府および公的機関による認知度向上への取り組み
  • 治療合併症を減らすための技術の進歩
• 市場の課題
  • 新興経済諸国における高度インフラの不足

ポーターのファイブフォース：生殖補助医療市場をナビゲートする戦略ツール

ポーターのファイブフォース」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：生殖補助医療市場における外部からの影響の把握

外部マクロ環境要因は、生殖補助医療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析生殖補助医療市場における競合情勢の把握

生殖補助医療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス生殖補助医療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、生殖補助医療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨生殖補助医療市場における成功への道筋を描く

生殖補助医療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ストレス、汚染、肥満による不妊症の増加
    • 新興国におけるヘルスケア費の上昇
    • 卵巣がん、子宮内膜がん、多嚢胞性卵巣症候群（PCOS）の罹患率の増加
  • 抑制要因
    • 手続きにかかる費用が高く、成功率が低い
  • 機会
    • 政府や公的機関による意識向上に向けた取り組み
    • 治療の合併症を減らすための技術的進歩
  • 課題
    • 新興経済諸国における先進インフラの不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 生殖補助医療市場：タイプ別

• 人工授精
• ドナー受精
• 配偶子卵管内移植
• 体外受精
• 排卵誘発
• 代理出産

第7章 生殖補助医療市場診断別

• 遺伝子検査
• ホルモン検査
• 子宮卵管造影検査
• 画像検査
• 卵巣予備能検査
• 排卵検査

第8章 生殖補助医療市場：エンドユーザー別

• クリニック
• 婦人科センター
• 病院
• 体外受精センター

第9章 南北アメリカの生殖補助医療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の生殖補助医療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの生殖補助医療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Carl Zeiss AG
• CCB Kitazato, LLC
• CooperSurgical, Inc. Cooper Companies Inc.
• Cryolab Ltd.
• Esco Micro Pte. Ltd.Esco Lifesciences Group
• Ferring B.V.
• FUJIFILM Irvine Scientific, Inc.
• Genea Limited
• INVO Bioscience
• Merck & Co., Inc.
• Nidacon International AB
• Planer PLC by Hamilton Thorne, Inc.
• Rocket Medical plc by Roko AB
• Thermo Fisher Scientific company
• Vitrolife AB

LIST OF FIGURES

• FIGURE 1. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET RESEARCH PROCESS
• FIGURE 2. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET DYNAMICS
• TABLE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ARTIFICIAL INSEMINATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DONOR CONCEPTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OVULATION INDUCTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SURROGACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HORMONE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HYSTEROSALPINGOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IMAGING TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OVARIAN RESERVE TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OVULATION TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GYNECOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILISATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 53. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 55. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. INDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. INDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 58. INDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 108. ITALY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ITALY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 110. ITALY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 120. POLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. POLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 122. POLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 123. QATAR ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. QATAR ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 125. QATAR ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 153. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 154. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2023

The Assisted Reproductive Technology Market was valued at USD 25.12 billion in 2023, expected to reach USD 29.52 billion in 2024, and is projected to grow at a CAGR of 17.57%, to USD 78.04 billion by 2030.

Assisted Reproductive Technology (ART) encompasses medical procedures used to address infertility, including in vitro fertilization (IVF), artificial insemination, and cryopreservation. The necessity of ART stems from rising infertility rates due to lifestyle changes, aging populations, and increased incidences of medical conditions like polycystic ovary syndrome. It is applied in clinics and hospitals to help individuals and couples conceive, catering primarily to families seeking to overcome various fertility challenges. The end-use sectors are primarily healthcare facilities and fertility centers. The market for ART is driven by advancements in medical technologies, growing awareness about fertility treatments, and increasing acceptance of ART procedures across various demographics. Additionally, governmental support and favorable regulations in many regions are contributing to market expansion. Key opportunities arise from technological innovations, such as AI and machine learning algorithms that enhance procedure success rates, and expanding services in emerging markets where fertility treatment demand is rising. However, challenges include high costs, ethical concerns, and limited access in certain regions, alongside a lack of skilled professionals in some areas. Additionally, societal and cultural stigmas can hinder adoption rates. Future innovations could focus on improving technique success rates, reducing costs, and personalizing treatments through genetic mapping and enhanced patient experience. Critical areas ripe for research and development include non-invasive diagnostic tools, improved embryo selection methods, and hormone therapy alternatives. For business growth, expanding services to emerging markets and investing in telehealth for initial consultations could prove beneficial. The ART market is dynamic, with significant growth potential, driven by technological advancements and the increasing prevalence of infertility. However, navigating ethical, cultural, and cost-related challenges will be crucial for sustained success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Assisted Reproductive Technology Market

The Assisted Reproductive Technology Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing number of infertility cases due to stress, pollution, and obesity
  • Rising healthcare expenditure across emerging nations
  • Increasing prevalence of ovarian & endometrial cancer and PCOS issues
• Market Restraints
  • High cost required for the procedure and lower success rate
• Market Opportunities
  • Initiatives from government and public organizations to increase awareness
  • Technological advancements to reduce the treatment complications
• Market Challenges
  • Dearth of advanced infrastructure in developing economies

Porter's Five Forces: A Strategic Tool for Navigating the Assisted Reproductive Technology Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Assisted Reproductive Technology Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Assisted Reproductive Technology Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Assisted Reproductive Technology Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Assisted Reproductive Technology Market

A detailed market share analysis in the Assisted Reproductive Technology Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Assisted Reproductive Technology Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Assisted Reproductive Technology Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Assisted Reproductive Technology Market

A strategic analysis of the Assisted Reproductive Technology Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Assisted Reproductive Technology Market, highlighting leading vendors and their innovative profiles. These include Carl Zeiss AG, CCB Kitazato, LLC, CooperSurgical, Inc. Cooper Companies Inc., Cryolab Ltd., Esco Micro Pte. Ltd.Esco Lifesciences Group, Ferring B.V., FUJIFILM Irvine Scientific, Inc., Genea Limited, INVO Bioscience, Merck & Co., Inc., Nidacon International AB, Planer PLC by Hamilton Thorne, Inc., Rocket Medical plc by Roko AB, Thermo Fisher Scientific company, and Vitrolife AB.

Market Segmentation & Coverage

This research report categorizes the Assisted Reproductive Technology Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Artificial Insemination, Donor Conception, Gamete Intrafallopian Transfer, In Vitro Fertilization, Ovulation Induction, and Surrogacy.
• Based on Diagnosis, market is studied across Genetic Testing, Hormone Testing, Hysterosalpingography, Imaging Testing, Ovarian Reserve Testing, and Ovulation Testing.
• Based on End User, market is studied across Clinics, Gynecology Centers, Hospitals, and In Vitro Fertilisation Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing number of infertility cases due to stress, pollution, and obesity
    • 5.1.1.2. Rising healthcare expenditure across emerging nations
    • 5.1.1.3. Increasing prevalence of ovarian & endometrial cancer and PCOS issues
  • 5.1.2. Restraints
    • 5.1.2.1. High cost required for the procedure and lower success rate
  • 5.1.3. Opportunities
    • 5.1.3.1. Initiatives from government and public organizations to increase awareness
    • 5.1.3.2. Technological advancements to reduce the treatment complications
  • 5.1.4. Challenges
    • 5.1.4.1. Dearth of advanced infrastructure in developing economies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Assisted Reproductive Technology Market, by Type

• 6.1. Introduction
• 6.2. Artificial Insemination
• 6.3. Donor Conception
• 6.4. Gamete Intrafallopian Transfer
• 6.5. In Vitro Fertilization
• 6.6. Ovulation Induction
• 6.7. Surrogacy

7. Assisted Reproductive Technology Market, by Diagnosis

• 7.1. Introduction
• 7.2. Genetic Testing
• 7.3. Hormone Testing
• 7.4. Hysterosalpingography
• 7.5. Imaging Testing
• 7.6. Ovarian Reserve Testing
• 7.7. Ovulation Testing

8. Assisted Reproductive Technology Market, by End User

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Gynecology Centers
• 8.4. Hospitals
• 8.5. In Vitro Fertilisation Centers

9. Americas Assisted Reproductive Technology Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Assisted Reproductive Technology Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Assisted Reproductive Technology Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Carl Zeiss AG
• 2. CCB Kitazato, LLC
• 3. CooperSurgical, Inc. Cooper Companies Inc.
• 4. Cryolab Ltd.
• 5. Esco Micro Pte. Ltd.Esco Lifesciences Group
• 6. Ferring B.V.
• 7. FUJIFILM Irvine Scientific, Inc.
• 8. Genea Limited
• 9. INVO Bioscience
• 10. Merck & Co., Inc.
• 11. Nidacon International AB
• 12. Planer PLC by Hamilton Thorne, Inc.
• 13. Rocket Medical plc by Roko AB
• 14. Thermo Fisher Scientific company
• 15. Vitrolife AB